DGAP-News: SYNLAB AG / Key word(s): Takeover/Expansion 
SYNLAB AG: SYNLAB and Medica Sur reach an agreement for SYNLAB to acquire 100 percent of Laboratorio Médico Polanco and 
Laboratorio Clinicos de Puebla 
2021-08-02 / 14:20 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . SYNLAB will acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla (LMP & LCR), a network of over 
    100 diagnostic service points in Mexico 
  . By integrating LMP & LCR into the international SYNLAB laboratory network, SYNLAB will strengthen its strategic 
    position in the region 
  . SYNLAB will be ideally structured and positioned for further expansion and integration of bolt-on acquisitions in 
    Mexico and Latin America 
SYNLAB, Europe's leading medical diagnostics services provider, with a presence in five Latin American countries, 
announces a corporate agreement with Medica Sur to acquire LMP & LCR to increase its presence to Mexico. 
With the scheduled acquisition, SYNLAB will incorporate LMP & LCR's dense network of more than 100 diagnostic service 
points mainly located around Mexico City and Puebla and employing 1,700 people. In 2020, LMP & LCR achieved revenues of 
MXP 1.3 billion (EUR 55 million), including COVID-19 testing services. 
SYNLAB will benefit from LMP's & LCR's excellent reputation gained from their long standing patient-centric approach to 
diagnostics and commitment to medical excellence. LMP & LCR deliver these high-end diagnostic services directly to 
patients via their regional network as well as by partnering with local hospitals and third party laboratories. In 
addition, LMP & LCR provide diagnostic services to corporate clients. 
The acquisition of LMP & LCR is an important milestone for SYNLAB's strategy in Latin America. Building up on this 
newly acquired platform in Mexico and an enthusiastic management team, SYNLAB will bolster cross-border cooperation in 
the region. 
Mathieu Floreani, CEO of SYNLAB, emphasises the strategic surplus of this acquisition for SYNLAB: "The incorporation of 
LMP & LCR into the SYNLAB network will further strengthen our position in Latin America. It will provide us with a good 
platform to expand our services in Mexico and beyond. We are also looking forward to welcoming a highly qualified and 
talented team to the SYNLAB family. With the support of the whole group, the new management team will continue or even 
accelerate SYNLAB's growth path in the region." 
The acquisition is subject to customary anti-trust approvals, with closing expected in Q4 2021. SYNLAB is well on track 
to exceed, in 2021, the EUR 200 million M&A target set as mid-term guidance. 
For more information: 
Media contact:              +49 (0) 151 46693856 
Diana Tabor, FTI Consulting diana.tabor@fticonsulting.com 
Investor contact:           +49 (0) 170 118 3753 
Mark Reinhard, SYNLAB       Mark.Reinhard@synlab.com About SYNLAB   . SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic

services company and offers a full range of innovative and reliable medical diagnostics for patients, practising

doctors, clinics and the pharmaceutical industry. . Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in

human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of

patients and customers. . SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than

20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as

biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB

carries out 500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020. . More information can be found on www.synlab.com -----------------------------------------------------------------------------------------------------------------------

2021-08-02 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1223360 
 
End of News   DGAP News Service 
=------------

1223360 2021-08-02


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223360&application_name=news

(END) Dow Jones Newswires

August 02, 2021 08:20 ET (12:20 GMT)